ResearcherJiangsu UniversityActive in the last 2 years

Min Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0001-5000-5921; OpenAlex author ID A5101387817. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

The m6A reader IGF2BP2 promotes pancreatic cancer progression through the m6A-SLC1A5-mTORC1 axis. Last author DOI 10.1186/s12935-025-03736-8 ↗
TTC22 as a potential prognostic marker and therapeutic target in pancreatic cancer: Insights into immune infiltration and epithelial‑mesenchymal transition. Last author DOI 10.3892/ol.2023.14143 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xi Pu · 1 shared paper, 2025 · strength 0.27
- Paper The m6A reader IGF2BP2 promotes pancreatic cancer progression through the m6A-SLC1A5-mTORC1 axis. DOI 10.1186/s12935-025-03736-8 ↗
Huizhi Wang · 1 shared paper, 2024 · strength 0.23
- Paper TTC22 as a potential prognostic marker and therapeutic target in pancreatic cancer: Insights into immune infiltration a… DOI 10.3892/ol.2023.14143 ↗
Yuntao Ding · 1 shared paper, 2024 · strength 0.23
- Paper TTC22 as a potential prognostic marker and therapeutic target in pancreatic cancer: Insights into immune infiltration a… DOI 10.3892/ol.2023.14143 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.